Professor Simon Coulton
Professor of Health Services Research Phone: 01227 824535
Email: S.Coulton@kent.ac.uk
A randomised, double-blind placebo-controlled trial of Memantine in the treatment of the agitation in Alzeimer's dementia
Chris Fox, Simon Coulton
Agitation in Alzheimer’s disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and mortality. There are no memantine trials in clinically significant agitation but post-hoc analyses in other populations found reduced agitation. We tested the primary hypothesis, memantine is superior to placebo for clinically significant agitation, in patients with moderate-to-severe AD.
Start date: 01/05/2006 End date: 31/07/2010
Funder: Lundbeck Ltd
Funding: £29,6707
Publication: Efficacy of Memantine for Agitation in Alzheimer’s Dementia: A Randomised Double-Blind Placebo Controlled Trial
back to top